Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

Watch the "What This Means" segment here

FRENCHTOWN, NJ / ACCESSWIRE / July 24, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor "What This Means" segment featuring Sonnet BioTherapeutics, Inc. (Nasdaq:SONN), a clinical-stage company developing targeted immunotherapeutic drugs.

As part of the "What This Means" segment, Pankaj Mohan, PhD, Founder and Chief Executive Officer, Richard Kenney, M.D., Chief Medical Officer and Dr. Gael Hedou, Chief Operating Officer of Sonnet BioTherapeutics, discuss highlights from the company's recently announced encouraging data from their ongoing Phase 1b/2a clinical trial of SON-080 in chemotherapy-induced Peripheral Neuropathy (CIPN).

The Virtual Investor "What This Means" segment featuring Sonnet BioTherapeutics is now available here. Additional videos from the "What This Means" series are available on demand at www.virtualinvestorco.com.

About JTC Team

JTC is a fully integrated corporate communications firm that is dedicated to helping you tell your story to the right audiences in order to build awareness. JTC has developed a reputation of excellence for executing robust communication strategies that deliver results. The Company partners with both public and private companies across the Life Sciences and Technology industries to help raise awareness and build stakeholder value. For more information, please visit www.jtcir.com or connect with the company on X and LinkedIn.

Contact:

Jenene Thomas
JTC Team, LLC
T: +1 (833) 475-8247
jtc@jtcir.com

SOURCE: JTC Team, LLC